戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              DTIC treatment, which did not increase FasR expression,
2  The CE ratio's 95% CI ranged from -$65,180 (DTIC is more effective) to $18, 670 per year of life gai
3 tients received 1.8 mg/kg BV and 375 mg/m(2) DTIC for up to 12 cycles, and 20 more patients received
4  vinblastine 1.6 mg/m2 daily for 4 days; and DTIC 800 mg/m2 intravenously (i.v.) day 1 with IL-2 9 x
5  malignant melanoma were treated with CDDP + DTIC + BCNU (CDB) with or without TAM.
6               The response rate of crossover DTIC treatment was 8.2%, with a median survival of 11.9
7 aline (NS) on days 1 to 3 of a 3-week cycle; DTIC 220 mg/m(2) IV for 1 hour in 500 mL of dextrose and
8 gents 5-fluorouracil (5-FU) and dacarbazine (DTIC) sensitize melanoma cells to lysis of G209 peptide-
9 mbination of carmustine (BCNU), dacarbazine (DTIC), cisplatin (DDP), and tamoxifen (Tam) has been rep
10 nt regimen of cisplatin (CDDP), dacarbazine (DTIC), and carmustine (BCNU) significantly increased the
11 s previously reported), BV plus dacarbazine (DTIC), and BV plus bendamustine.
12    Patients crossed over to the dacarbazine (DTIC) treatment after disease progression following firs
13 d control patients treated with dacarbazine (DTIC), median overall survival of 15.0 versus 8.3 months
14 cal costs were included and increased 50% if DTIC's efficacy was unchanged if given as a single daily
15 for 5 days every 28 days or intravenous (IV) DTIC at a starting dosage of 250 mg/m(2)/d for 5 days ev
16 temozolomide than after IV administration of DTIC.
17 omide demonstrates efficacy equal to that of DTIC and is an oral alternative for patients with advanc
18 s in the range reported for single agents or DTIC plus DDP, and the addition of BCNU and Tam appears
19                       Treatment with 5-FU or DTIC sensitized melanoma cells to lysis of G209-specific
20                   Most importantly, 5-FU- or DTIC-treated melanoma cells also became sensitive to low
21    The mean increase in survival of TEM over DTIC was 1.1 months.
22        For elderly patients with HL, BV plus DTIC may be a frontline option based on tolerability and
23                                  For BV plus DTIC, the objective response rate (ORR) was 100% and the
24 costs per patient were greater with TEM than DTIC ($6,902 v $3,697, respectively).
25  and costs, direct nonmedical costs, and the DTIC schedule.
26 omide-treated group (1.9 months) than in the DTIC-treated group (1.5 months) (P =.012; hazards ratio,
27 reated with BCNU 150 mg/m2/d, every 6 weeks, DTIC 220 mg/m2/d on days 1 to 3 every 3 weeks, DDP 25 mg
28  the base-case efficacy of TEM compared with DTIC was not statistically significant, its associated i
29 lomide and 6.4 months for those treated with DTIC (hazards ratio, 1.18; 95% confidence interval [CI],
30 dian survival times of patients treated with DTIC and TEM were 6.4 and 7.7 months, respectively (HR =

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。